Clinical and Hematological Profiles During Valproate Treatment of Epileptic Patients with Intellectual Disability — Case Study and Mini Review by P. Kaipainen et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Provisional chapter
Clinical and Hematological Profiles During Valproate
Treatment of Epileptic Patients with Intellectual
Disability — Case Study and Mini Review
P. Kaipainen, T. Westermarck, F. Atroshi,
M. Kaski and M. Iivanainen
Additional information is available at the end of the chapter
1. Introduction
Valproic acid or sodium valproate (VPA) is an antiepileptic drug commonly used for treatment
of epilepsies [Aldenkamp et al. 2006; Ben-Menachem et al. 2006; Iivanainen & Alvarez 1998;
Perucca et al. 2006). It affects the function of the neurotransmitter GABA in the human brain
by enhancing the neurotransmission of GABA (Rosenberg, 2007). VPA is known to cause many
harmful side effects such as hepatotoxicity (Koenig et al. 2006) and carnitine deficiency
(Coppola et al. 2006). Carnitine as a healing agent has begun to play an important role in VPA-
induced hepatotoxicity. When signs of hepatotoxicity occur, it is important to discontinue VPA
immediately and substitute carnitine i.v (Koenig et al. 2006). Inhibitions of the β-oxidation,
oxidative phoshorylation and urea synthesis and a decrease of intracellular carnitine are
supposed to induce hepatopathy (Cotarlu & Zaldman 1988; Hjelm et al. 1987; Murakami et al.
1996). It has been reported that urinary concentration of a VPA metabolite, 4-en VPA, is
markedly increased in acute VPA intoxication (Murakami et al. 1996). It is believed that this
metabolite of VPA is responsible for developing hepatotoxicity. VPA metabolism returns to
normal after L-carnitine supplementation (Murakami et al. 1996). Thurston & Hauhart 1993
reported that a reduction of intracellular CoA may be the central common pathway for VPA-
induced hepatotoxicity.
The clinical relevance of coagulopathies, known as side effects of VPA, especially thrombo‐
cytopenia, von Willebrand disease and a decrease of factor XIII, is still unclear (Gerstner et al.
2006). The incidence of coagulation disorders related to VPA in children is estimated to be
nearly 4% (Gerstner et al. 2006).
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It has been reported that VPA may be associated with hyperammonemia and thrombocyto‐
penia, but the aetiology of valproic acid-induced thrombocytopenia has not been elucidated
(Mallet et al. 2004). In patients receiving long-term VPA VPA-induced hyperammonaemic
encephalopathy may occur (Lheureux et al. 2005). It is suggested that this severe side-effect
may be promoted by a pre-existing carnitine deficiency or by deficiency induced by VPA
(Lheureux et al. 2005). Because the onset of the clinical symptoms of VPA-associated hepato‐
toxicity, especially in patients with intellectual disability, is sudden and unpredictable, the aim
of our study was to find out suitable biochemical and haematological markers to prevent this
state of illness.
2. Case presentation
Blood samples for assays of sodium (Na), potassium (K), aspartate aminotransferase (ASAT),
alanine aminotranferase (ALAT), amylase, alkaline phosphatase, c-reactive protein (CRP),
creatinine, haemoglobin, mean cell volume, haematocrit, erythrocytes, thrombocytes and
leukocytes were obtained from ID patients with epilepsy and on VPA and from healthy
persons of hospital staff after overnight fasting. All patients in this study used VPA as a
monotherapy. Vacuette serum tubes were used to obtain serum samples and vacuette K2EDTA
tubes were used to obtain haematological samples. All assays were made immediately after
sampling in the same day. The whole large patient material was from Rinnekoti hospital,
Espoo-Finland. Sex and age varied in the VPA and control groups. Approximately 50% from
the whole patient and control material was male. The mean ages for the VPA group and the
control group were 37±15 years and 50±10 years, respectively. Laboratory determinations and
reagents:Serum sodium (Na), potassium (K), aspartate aminotransferase (ASAT), alanine
aminotransferase (ALAT), amylase, alkaline phosphatase, c-reactive protein (CRP) and
creatinine were analyzed with Cobas Mira analyzer. Haemoglobin, mean cell volume (MCV),
hematocrit, erythrocytes, thrombocytes and leukocytes were assayed with Sysmex KX-21N
analyzer. All used reagents were reagent grade. All laboratory determinations were controlled
with the control samples from Labquality Ltd, Helsinki, Finland.
3. Discussion and review
The levels of CRP and potassium (K) were higher while haematocrit and contents of throm‐
bocytes and erythrocytes and the levels of sodium (Na), creatinine and haemoglobin were
lower in the VPA group compared with the control group. All results of 14 clinical and
haematological markers are shown in table 1. The results showed that thrombocyte and
erythrocyte counts, haematocrit and the levels of sodium (Na), creatinine and hemoglobin
were lower in the VPA group compared with the control group. Differences in haematocrit
and thrombocyte and erythrocyte counts were statistically extremely significant so that these
determinations besides assay of serum free carnitine can be used as markers to evaluate VPA
toxicity. The haematological profile is the most common investigations patients undergo.
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Many structural, biochemical and physiological changes take place in the brain following head
trauma which in turn account for epileptogenesis (Katayama et al. 1990). For example, seizures
occur in rats shortly after traumatic injury lead to increase in glutamate and aspartate levels
which explain possible involvement in epileptogenesis (Nilson et al. 1994). Antiepileptic drugs
affect hepatic enzyme levels in patients known to have a coexisting hepatic abnormality, those
who develop symptoms of hepatic involvement while receiving AEDs, and perhaps those
receiving bitherapy with high serum AED levels (Verma & Haidukewych, 1994). Rao et al.
(1993) reported 72% of the AED-treated patients and 33% of the unmedicated patients showed
an increase in one or several serum liver enzymes [alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and/or gamma-glutamyl transferase (gamma-GT)]; particularly
gamma-GT.
The World Health Organisation defines anaemia as < 13 g Hb/dL for men and < 12 g Hb/dL
for women (2001), accepting that women generally have lower haemoglobin concentrations
than men. However, when ferritin levels (Waalen et al. 2002), is considered then the difference
may be due to hormonal influences on red cell production (Shahidi, 1973), the do not support
this (Waalen et al. 2002). Platelet counts have been found to be significantly higher in women
(Butkiewicz et al.2006), with possible explanations of increased thrombopoietin in women
being reported. Total leukocyte count showed to be significantly higher in women than men
due to a highly significant difference in neutrophil count, with no significant correlation
between monocytes, basophils and gender (Bain & England, 1975).
This study is in line with the earlier observations that VPA may induce thrombocytopenia
(Koenig et al. 2006; Gerstner et al. 2006; Mallet et al. 2004). According to Gerstner et al. 2006
thrombocytopenia is the most common haematological adverse effect of VPA. An incidence
varies from 5% to 60% (Gerstner et al. 2006; Zeller et al. 1999). It is suggested that there are two
possible mechanisms inducing thrombocytopenia. First mechanism is that VPA have a direct
toxic effect on bone marrow (Gertsner et al. 2006). Second mechanism is that VPA seems to
induce the formation of autoantibody against platelets (Sandler et al. 1978). We found that
contents of thrombocytes and erythrocytes lowered approximately 30 % and 10 %, respective‐
ly, in patients on VPA monotherapy. This observation supports the hypothesis that VPA seems
to have a direct toxic effect on bone marrow (Gerstner et al. 2006).
To prevent severe hepatotoxicity in patients on long-term VPA therapy, it is important to
control contents of thrombocytes and erythrocytes and to determine the level of serum free
carnitine, regularly. If the level of serum free carnitine and the thrombocyte counts are lowered,
addition of carnitine to long-term VPA regimen of epileptic patients may be indicated. Further
investigations are needed to evaluate appropriate dosages of L-carnitine supplementation to
epileptic patients on long-term VPA therapy.
Valproic acid (N-dipropylacetic acid, or 2-propylpentanoic acid) is one of the mainstays of
therapy for epilepsy and bipolar mood disorders, due to its anticonvulsant and mood-
stabilizing effects (Blaheta & Cinatl, 2002). It is a branched short-chain fatty acid with a half-
life of 9 to 16 hours. Clinically, VPA is usually administered as uncoated tablets, but may also
be administered in the form of syrup, capsules and enteric-coated tablets. Ninety per cent of
VPA in the blood is bound to albumin (Cramer & Mattson, 1979), and despite its hydrophilic
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nature enters the CNS by crossing the blood brain barrier via passive diffusion and bidirec‐
tional carrier-mediated transport, such as an anion exchanger at the brain capillary endothe‐
lium (Perucca, 2002). VPA crosses into the brain parenchyma utilizing another set of
transporters which results in higher neuronal and glial concentrations than interstitial fluid
concentrations (Perucca, 2002). VPA, in addition to being an effective anticonvulsant and
mood-stabilizing agent has been shown to be an effective anxiolytic (Lal et al., 1980), antidys‐
tonic and antinociceptive (Loscher, 1999), in animal studies. Clinically, VPA is effective in
clinical depression (Delucchi & Calabrese, 1989), absence seizures (Coppola et al., 2004), tonic-
clonic seizures, complex partial seizures (Dean & Penry, 1988), and juvenile myoclonic epilepsy
(Calleja et al., 2001).
4. Haematological toxicity of valproic acid
Valproic acid has been shown to have some haematological toxicity. Acute toxicity is not
common and the most adverse effects are nausea, vomiting, anorexia, thrombocytopenia,
von Willebrand disease  type 1,  decreased factor  XIII,  abnormal  platelet  function,  bleed‐
ing,  haemolytic  anaemia,  leukopenia,  leucocytosis,  eosinophilia,  thrombocytosis,  pro‐
longed prothrombin and thromboplastin times, fibrinogen and hematoma (Kreuz et al 1992;
Gerstner et al. 2006; Gerstner et al, 2008; Pan et al 2007; Mazaira, 2008; Chen et al. 2013).
However, some of these effects may lead to adverse effects and life-threatining complica‐
tions  such  as  bone  marrow  toxicity  (Acharya  &  Bussel,  2000).  Pharmacokinetics  drug
interaction involves a drug displacement from protein binding sites causing drug redistrib‐
ution (McQueen & Wardell,  1971).  Valproic  acid  is  commonly used in  the  treatment  of
seizures and as a mood stabilizer in the treatment of manic depression.
Our  study  presents  interesting  clinical  findings.  Laboratory  tests  confirmed  macrocytic
anaemia.  Thrombocytes  concentrations  were  decreased,  but  other  biochemical  measure‐
ments such as haemoglobin were within the normal range (Table1). However, Taher et al.
(2009) reported an association between divalproex sodium (DVPX) therapy and total Hb
level. It has been reported that in patients treated with VAP 18% experienced at least one
episode  of  thrombocytopenia  (Nasreddine  &,  Beydoun,  2008).  However,  Rahman  et  al.
(2009) reported 26% of his patients experienced leukopenia. The haematological complica‐
tions in patients treated with VAP appear to be heterogenic depending on the period of
treatment, taking other anticonvulsants, or additional medications (Hemingway et al. 1999;
Antoniou et al.  2004). Valporic acid is able to alter hematopoiesis by inhibition of eryth‐
roid differentiation in the experimental K562 cell linkage (Chateauvieux et al. 2011). Ladd
et al (2009) reported that an elevated level of creatinine phosphokinase is not required for
a DSM-IV diagnosis of neuroleptic malignant syndrome (Ladds et al.2009).  In our study
creatinine phosphokinase was at  levels  70 U/I  compared to 82 U/l  in controls.  A creati‐
nine phosphokinase level of 800,000 U/l was reported for a patient who was being treated
with a conventional antipsychotic (Sanai et al. 2006).
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Determinations Patients (M±SD) (n) Controls (M±SD) (n) p-value
Thrombocytes (E9/l) 186±67  (141) 259±59  (367) 1.4×10-23
Erythrocytes (E12/l) 4.1±0.43  (140) 4.5±0.4  (217) 2.1×10-10
Hematocrit 0.38±0.04  (142) 0.4±0.03  (217) 4.0×10-7
Sodium (Na) (mmol/l) 136±5.5  (49) 140±1.4 (49) 0.000016
Potassium (K) (mmol/l) 4.4±0.4  (49) 4.1±0.3  (49) 0.000038
Hemoglobin (g/l) 132±15  (142) 138±12  (217) 0.000100
C-reactive protein (CRP) (mg/l) 28±32  (64) 10±18  (136) 0.000130
Creatinine (µmol/l) 70±13  (13) 82±14  (50) 0.007600
Mean cell volume (MCV) (fl) 92±3.9  (142) 91±5.0  (217) 0.028500
Alanine aminotransferase (ALAT) (U/L) 21±18  (65) 41±90  (86) 0.044850
Alkaline phosphatase (AFOS) (U/L) 150±53  (16) 125±41  (25) 0.134720
Leukocytes (E9/l) 6.2±2.5  (140) 6.5±2.5  (217) 0.197680
Aspartate aminotransferase (ASAT) (U/L) 26±14  (38) 31±22  (29) 0.330570
Amylase (U/L) 205±45  (42) 192±75  (29) 0.399700
M=mean value
SD=standard deviation
n=number of observations
Table 1. The levels of eight clinical and six hematological markers in patients on VPA and in control
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